295 related articles for article (PubMed ID: 31645666)
1. Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation.
Chen F; Sun J; Yin C; Cheng J; Ni J; Jiang L; Wang Q; Yu G; Wei Y; Liu X; Sun J; Carter BZ; Jiang X
Bone Marrow Transplant; 2020 Apr; 55(4):740-748. PubMed ID: 31645666
[TBL] [Abstract][Full Text] [Related]
2. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
3. Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation.
Khanolkar RA; Faridi RM; Kinzel M; Jamani K; Savoie ML; Shafey M; Khan FM; Storek J
Cytotherapy; 2022 Apr; 24(4):413-420. PubMed ID: 34863627
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia.
Oran B; Cortes J; Beitinjaneh A; Chen HC; de Lima M; Patel K; Ravandi F; Wang X; Brandt M; Andersson BS; Ciurea S; Santos FP; de Padua Silva L; Shpall EJ; Champlin RE; Kantarjian H; Borthakur G
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1218-1226. PubMed ID: 27058617
[TBL] [Abstract][Full Text] [Related]
5. FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Propensity Score- Matching Study.
Zhou C; Zheng F; Xu L; Zhang X; Chang Y; Mo X; Sun Y; Huang X; Wang Y
Transplant Cell Ther; 2023 Jul; 29(7):456.e1-456.e11. PubMed ID: 37028555
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of low allelic ratio
Sakaguchi M; Yamaguchi H; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Gomi S; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Nakajima N; Marumo A; Omori I; Fujiwara Y; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
Blood Adv; 2018 Oct; 2(20):2744-2754. PubMed ID: 30341082
[TBL] [Abstract][Full Text] [Related]
10. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
[TBL] [Abstract][Full Text] [Related]
11. [Influence of FLT3-ITD Mutation and ITD Length on the Outcome on Patients with Acute Myeloid Leukemia].
Chen F; Jiang XJ; Yin CX; Zhong QX; Jiang L; Yu GP; Sun J; Meng FY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):678-683. PubMed ID: 29950203
[TBL] [Abstract][Full Text] [Related]
12. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.
Versluis J; In 't Hout FE; Devillier R; van Putten WL; Manz MG; Vekemans MC; Legdeur MC; Passweg JR; Maertens J; Kuball J; Biemond BJ; Valk PJ; van der Reijden BA; Meloni G; Schouten HC; Vellenga E; Pabst T; Willemze R; Löwenberg B; Ossenkoppele G; Baron F; Huls G; Cornelissen JJ
Leukemia; 2017 Jan; 31(1):26-33. PubMed ID: 27416910
[TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
14. Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation.
Jiang G; Capo-Chichi JM; Liu A; Atenafu EG; Kumar R; Minden MD; Chang H
Biol Blood Marrow Transplant; 2020 Nov; 26(11):1995-2000. PubMed ID: 32712325
[TBL] [Abstract][Full Text] [Related]
15. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
[TBL] [Abstract][Full Text] [Related]
17. Adverse impact of a high allelic burden FLT3-ITD mutation on allogeneic hematopoietic stem cell transplantation in patients with cytogenetically normal AML.
Wan L; Ding S; Xu M; Lv K; Du Y; Wu D; Xu M; Liu Y
Int J Hematol; 2022 Nov; 116(5):731-743. PubMed ID: 35857193
[TBL] [Abstract][Full Text] [Related]
18. FLT3 and NPM1 mutations in Chinese patients with acute myeloid leukemia and normal cytogenetics.
Wang L; Xu WL; Meng HT; Qian WB; Mai WY; Tong HY; Mao LP; Tong Y; Qian JJ; Lou YJ; Chen ZM; Wang YG; Jin J
J Zhejiang Univ Sci B; 2010 Oct; 11(10):762-70. PubMed ID: 20872983
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation.
Liu YC; Hsiao HH; Lin PM; Yang WC; Chang CS; Liu TC; Hsu JF; Yang MY; Lin SF
Genet Mol Res; 2013 Nov; 12(4):5414-23. PubMed ID: 24301914
[TBL] [Abstract][Full Text] [Related]
20. Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Pasic I; Da'na W; Lam W; Law A; Lipton JH; Viswabandya A; Kim DD; Thyagu S; Messner HA; Michelis FV
Eur J Haematol; 2019 Apr; 102(4):368-374. PubMed ID: 30706524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
